Business Context and Reporting Period
This Form 8-K, dated January 2, 2019, reports that Bristol-Myers Squibb Company (BMS) entered into a definitive Merger Agreement with Celgene Corporation. The transaction involves BMS acquiring Celgene through a merger with a wholly-owned subsidiary, with Celgene surviving as a subsidiary of BMS.
Key Financial Metrics and Transaction Terms
The filing details the consideration and financing structure for the acquisition rather than historical operating results.
- Consideration per Celgene Share: $50.00 in cash, one share of BMS common stock, and one Contingent Value Right (CVR).
- Contingent Value Rights (CVRs): Entitle holders to receive $9.00 in cash per share if specific FDA approval milestones are met for three products (JCAR017, Ozanimod, and BB2121) by December 31, 2020, or March 31, 2021.
- Financing: BMS secured a $33.5 billion 364-day senior unsecured bridge term loan facility from Morgan Stanley Senior Funding, Inc. and MUFG Bank, Ltd. to finance the acquisition.
- Termination Fees: A fee of $2.2 billion is payable by either party under specific termination scenarios (e.g., superior proposals or change in recommendation).
Note: This filing does not provide specific revenue, profit, cash flow, margin, or debt figures for BMS or Celgene.
Material Changes and Conditions
The transaction is subject to customary closing conditions, including:
- Adoption of the Merger Agreement by a majority of Celgene stockholders.
- Approval of the BMS stock issuance by a majority of BMS stockholders.
- Regulatory approvals, including the expiration of the Hart-Scott-Rodino waiting period and antitrust approvals in other jurisdictions.
- Listing approval for BMS stock and CVRs on the New York Stock Exchange.
The agreement includes a "drop-dead" date of January 2, 2020, subject to extensions if regulatory approvals are delayed.
Outlook, Risks, and Management Commentary
Management has agreed to use "Diligent Efforts" to achieve the CVR milestones. The filing includes extensive forward-looking statements regarding anticipated synergies, accretion to non-GAAP earnings per share, and the combined company's capital structure. However, these projections are based on estimates and are subject to significant uncertainties.
Key Risks Identified:
- Failure to satisfy closing conditions or obtain regulatory approvals.
- Inability to achieve projected synergies or successfully integrate Celgene's business.
- Disruption to operations and diversion of management attention.
- Potential decline in credit ratings of the combined company.
- Uncertainty regarding the timing and probability of CVR payments.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and CVR Agreement in the upcoming Form S-4 joint proxy statement/prospectus.
- Monitor the status of regulatory approvals, particularly antitrust reviews under the Hart-Scott-Rodino Act.
- Track the progress of clinical trials and FDA approval timelines for JCAR017, Ozanimod, and BB2121 to assess CVR payout probability.
- Review the definitive financing terms once the bridge facility is drawn or permanent financing is secured.
- Confirm the outcome of stockholder votes at both BMS and Celgene.